2018 GBT 034 – An Open-label Extension Study of Voxelotor (GBT 440) Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials (GBT440-034)
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros.
Previous Post2017 GBT 031 – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study of GBT 440 Administered Orally to Patients with Sickle Cell Disease
Next Post2020 IMR-SCD-301 ‘IMARA’ – A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
